Navigation Links
Schizophrenia drugs raise the volume of a key signaling system in the brain
Date:5/12/2010

All the major groups of medications for schizophrenia turn up the volume of a brain signal known to be muted in individuals with this psychiatric disorder a signal that also can be influenced by diet. "This is the first example of a common but specific molecular effect produced by all antipsychotic drugs in any biological system," scientists note in the current edition of ACS Chemical Neuroscience, a monthly journal.

In the report, Eric J. Aamodt and colleagues explained that scientists know little about how antipsychotic drugs work, aside from the drugs' effects on one signaling chemical called dopamine. New studies, for instance, suggested that medications like olanzapine, quetiapine, and clozapine also affect other signaling systems in the brain. These systems, including one termed the Akt signaling pathway, influence behavior by regulating communication between brain cells. To fill those gaps in knowledge, the scientists turned to genetically modified forms of a worm, C. elegans, often used as a stand-in for people in such research. The tiny creatures were wired to glow green to show activity of Akt, a signal that is too quiet in schizophrenic brains.

They found that all of the 13 antipsychotic drugs tested, representative of all major categories of antipsychotic medications, helped the worms maintain their characteristic green glow. The results highlight the importance of Akt signaling in schizophrenia, suggesting that medications or other approaches that increase Akt signaling might help to alleviate the symptoms of schizophrenia. Other labs have identified certain dietary measures that may also increase Akt signaling.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert  

Page: 1

Related biology news :

1. Impaired brain connections traced to schizophrenia mutation
2. Scientists identify age-associated defects in schizophrenia
3. Research builds on genetic link to autism and schizophrenia
4. Blood test for schizophrenia could be ready this year
5. Gene linked to schizophrenia may reduce cancer risk
6. CSHL-led team discovers rare mutation dramatically increasing schizophrenia risk
7. Scientists demonstrate link between genetic defect and brain changes in schizophrenia
8. A genetic basis for schizophrenia
9. LSUHSC research helps link schizophrenia to specific DNA region
10. Flow of potassium into cells implicated in schizophrenia
11. Altered gene can increase risk of schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Schizophrenia drugs raise the volume of a key signaling system in the brain
(Date:3/2/2017)... , March 2, 2017 Summary ... to better understand Merck KGaA and its partnering interests ... https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals and ... the partnering activity of one of the world,s leading ... are prepared upon purchase to ensure inclusion of the ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
(Date:2/28/2017)... 2017   Acuant , a leading provider of ... enhancements to new and core technologies building upon the ... mobile and desktop Acuant FRM TM facial recognition ... real time manual review of identity documents by accredited ... fastest and most accurate capture software to streamline workflows ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... GREENWOOD VILLAGE, Colo. , March 23, 2017 /PRNewswire/ ... million in Series A financing and note conversion to ... products. Cool Planet is focused on developing products that ... raised nearly $30 million in the last 18 months. ... Coppel and North Bridge Venture Partners. ...
(Date:3/22/2017)... March 22, 2017  Ascendis Pharma A/S (Nasdaq: ... TransCon technology to address significant unmet medical needs ... the full year ended December 31, 2016. ... our company as we broadened our pipeline and ... rare disease company with an initial focus on ...
(Date:3/22/2017)... , March 22, 2017 ... fragmented, states a research report by Transparency Market Research ... Inc., Amgen Inc., and AbbVie Inc., accounted for a ... The prominent players in this market are focusing aggressively ... product portfolio, which is likely to lead to market ...
(Date:3/22/2017)... (PRWEB) , ... March 21, 2017 , ... Premier executive ... & Life Science Search Firm by Hunt Scanlon Media. , Hunt Scanlon ... and the most widely referenced global news source in the human capital sector. , ...
Breaking Biology Technology: